• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·600080.SS
Share

Ginwa Enterprise Stocks

CN¥ 4.82Last Updated 21.09.2026

Issuer Rating

3/7
Performance

Poor

Risk

Limited

Recommendation

Sell

Market Cap

CN¥ 265.86M

CN¥ 4.82
Key Takeaways

Risk factor

Resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Ginwa Enterprise (Group) Inc. is a pharmaceutical company that specializes in the research, development, manufacturing, and commercialization of traditional Chinese, biological, and chemical medicines within China. The company's diverse product line encompasses treatments for a broad spectrum of medical conditions, including those related to orthopedics, immune system function, pediatric care, infectious diseases (such as antibiotics and antivirals), digestive health, gynecological issues, and cardiovascular ailments, as well as offerings for fever and pain relief. These medications are distributed in various common forms, specifically capsules, powders, and tablets. Ginwa Enterprise (Group) Inc. maintains its headquarters in Xi'an, China.

Company Valuation

Greatly overvalued
1/7

Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITD.

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

21.09.2026 17:00

Diversification Is an Illusion: How Does "Smart Money" Invest in a Market Dominated by AI?

21.09.2026 16:50

Shares of three micro-cap companies with projects in Greenland have skyrocketed. Trump drove up their prices.

21.09.2026 16:22

AI 'in most cases' gives incorrect answers to financial questions, study finds

21.09.2026 15:37

Morning in New York: Optimism Drives Market Prices

21.09.2026 14:53

German stocks rose despite the chancellor's party's poor showing in the election. What's going on?

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026